Retrospective Review of Esophageal Cancer at MSKCC

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jan 23, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how the circumferential resection margin (CRM) affects outcomes for patients with esophageal cancer who have had surgery to remove part of their esophagus. The CRM is the edge of the tissue that is removed during surgery, and researchers want to understand its importance in predicting survival for patients who have certain types of esophageal cancer, specifically those with more advanced tumors.

To participate in this study, individuals must have a specific type of esophageal cancer called esophageal adenocarcinoma or esophageal squamous cell carcinoma, and their tumors must be at least a certain size (classified as T3). Unfortunately, people with less advanced tumors or other types of cancer, as well as those who have had previous surgeries for their cancer, may not be eligible. Participants in this study will help researchers gather important information that could improve the understanding and treatment of esophageal cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
• • Pathologic staged T3 tumors (pT3)
• Exclusion Criteria:
• • Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
• • Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
• • Patients undergoing salvage esophagectomy
• • Evidence of distant metastatic disease
• • Patients with a positive proximal or distal margin